Phase 2Completed

Randomized Study of Obicetrapib in Combination With Ezetimibe (OCEAN)

A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia

Sponsor
NewAmsterdam Pharma (Industry)
Enrollment
112 enrolled
Conditions
Dyslipidemias; High Cholesterol; Hypercholesterolemia
Interventions
Obicetrapib 5mg; Ezetimibe 10mg; Placebo
Ages
adults, older adults
Registry
NCT04770389

Full record on ClinicalTrials.gov

From the registry

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.

Primary outcomes

  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
  • Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
  • LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started